JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
about
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerSuppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cellsA phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancerSatraplatin: an orally available platinum analog for the treatment of cancer.Satraplatin in the treatment of hormone-refractory metastatic prostate cancerAnticancer activity of metal complexes: involvement of redox processes.The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate CancerChemotherapy Resistance in Lung Cancer.A novel oxaliplatin derivative, Ht-2, triggers mitochondrion-dependent apoptosis in human colon cancer cells.Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21(waf1/cip1)-independent pathway in human colorectal cancer cells.Comparison of the cytotoxic effects of Juniperus sabina and Zataria multiflora extracts with Taxus baccata extract and Cisplatin on normal and cancer cell lines.Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagyNuclear Factor-kappa B as a Resistance Factor to Platinum-Based Antineoplasic Drugs.The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.Can Satraplatin be hydrated before the reduction process occurs? The DFT computational study.Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance.Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor
P2860
Q28396304-2900ED42-9196-4402-9806-D89025C6A6F2Q35051543-AAF83EDD-21DF-4461-8D10-AADAC45869EBQ36428631-630D1E29-2BC5-4B9A-AC44-17402A46B49DQ36532071-9C508E27-CE08-4231-8A98-A299872CC28EQ37160386-E8200918-F7D6-4664-A514-055570B56C7FQ37833099-1A354569-3173-4EA7-9414-4525B50C5E37Q38639852-6083C925-9376-4C9F-8B1B-311C18537AAEQ38669287-C3C9317B-8812-40EB-A79C-EC60210C1369Q38948725-0B352778-B7D0-40A6-B383-C727B0974DC6Q39018004-CF2A15E8-EE9A-4B41-88FF-8748B1F84B66Q39674090-88D180D3-ABAD-403E-8E81-5E65373768E3Q41911830-F4EB2D5D-8074-4CEC-82F2-52388F19A461Q43110174-D74F2D69-B270-463C-AE38-443AAA35616AQ49123833-DAEE123E-FFDC-4526-AE4E-F22DAE0CF8A3Q51362514-E8380D82-7BE7-4292-BE2F-B0EC0EDD91A8Q53304624-1934AA40-BCB5-47AD-97BD-87CFADF6A827Q58993871-1BA91F78-872A-44B2-8CF1-A45D7D3BB049
P2860
JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
JM216-, JM118-, and cisplatin- ...... nt sensitivities to cisplatin.
@en
type
label
JM216-, JM118-, and cisplatin- ...... nt sensitivities to cisplatin.
@en
prefLabel
JM216-, JM118-, and cisplatin- ...... nt sensitivities to cisplatin.
@en
P2093
P1476
JM216-, JM118-, and cisplatin- ...... ent sensitivities to cisplatin
@en
P2093
Coby Meijer
Eelco Fokkema
Harry J M Groen
Marco N Helder
P304
P356
10.1016/S0006-2952(02)00983-8
P407
P577
2002-06-01T00:00:00Z